Literature DB >> 3039199

Phase 2 study of high dose etoposide (VP16-213) in hepatocellular carcinoma.

W Shiu, S D Mok, N Leung, M Li, A Zacharia, A Li, C Martin.   

Abstract

A phase II study of etoposide (VP16-213) in hepatocellular carcinoma was conducted among 18 Chinese patients. There was no observable tumour response but the treatment was relatively well tolerated with an overall median survival interval of 74 days.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3039199

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN： 0368-2811            Impact factor:   3.019


  4 in total

1.  Grey Turner Memorial Lecture. Changing role of liver surgeons.

Authors:  A K Li
Journal:  World J Surg       Date:  1999-01       Impact factor: 3.352

Review 2.  Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

Authors:  J M Henwood; R N Brogden
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

3.  Phase II study of high-dose ifosfamide in hepatocellular carcinoma.

Authors:  J Lin; W Shiu; W T Leung; M Tao; N Leung; W Y Lau; A K Li
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 4.  Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma.

Authors:  Takuji Torimura; Hideki Iwamoto; Toru Nakamura; Hironori Koga; Takato Ueno; Robert S Kerbel; Michio Sata
Journal:  Transl Oncol       Date:  2013-10-01       Impact factor: 4.243
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.